Edesa Biotech, Inc.
NASDAQ:EDSA · NASDAQ Capital Market
+$0.09 today
Vol 0.25M · Avg 0.62M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-57.7%
avg -101.2%
ROIC
-63.5%
avg -113.4%
ROA
-53.1%
avg -75.7%
Analysis
ROA is currently the strongest return metric at -53.1% versus its period average of -75.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Pardeep Nijhawan FRCPC | Chief Executive Officer, Company Secretary & Director | $483,828.00 | — | 55 | $884,684.00 | 9.95% |
Michael J. Brooks | President | $450,206.00 | — | 47 | $129,609.00 | 1.46% |
Peter John Weiler | Chief Financial Officer | $310,558.00 | — | 57 | $129,609.00 | 1.46% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$226,455.15
Sells
0
$0.00
Net Sentiment
+$226,455.15
Net buying
Most Active
Nijhawan Pardeep
7 transactions
Analysis
Insiders reported 8 buys worth $226,455.15 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $226,455.15. Nijhawan Pardeep was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +38.4% | +27.9% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +38.4% over three years. Forward estimates point to Revenue at +27.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Sensei Biotherapeutics, Inc.
SNSE
$18.59M
Cocrystal Pharma, Inc.
COCP
$10.09M
OSR Holdings, Inc.
OSRH
$9.43M
Traws Pharma, Inc.
TRAW
$7.01M
Immuron Limited
IMRN
$6.80M
Imunon, Inc.
IMNN
$4.77M
Evogene Ltd.
EVGN
$4.40M
BioRestorative Therapies, Inc.
BRTX
$3.54M
Dogwood Therapeutics, Inc.
DWTX
$2.81M
Ernexa Therapeutics Inc.
ERNA
$1.82M
Who manages EDSA?
Edesa Biotech, Inc. (EDSA) lists 3 active executives. The top listed executive is Peter John Weiler, Chief Financial Officer.
Are EDSA insiders buying or selling?
Recent insider activity shows net buying of $9.05M.
Explore More
Continue the stock analysis
Jump to another research area for this company.